JP2016508026A5 - - Google Patents

Download PDF

Info

Publication number
JP2016508026A5
JP2016508026A5 JP2015542310A JP2015542310A JP2016508026A5 JP 2016508026 A5 JP2016508026 A5 JP 2016508026A5 JP 2015542310 A JP2015542310 A JP 2015542310A JP 2015542310 A JP2015542310 A JP 2015542310A JP 2016508026 A5 JP2016508026 A5 JP 2016508026A5
Authority
JP
Japan
Prior art keywords
pca
category
composite value
biomarker
snppc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015542310A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016508026A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/074270 external-priority patent/WO2014079874A1/en
Publication of JP2016508026A publication Critical patent/JP2016508026A/ja
Publication of JP2016508026A5 publication Critical patent/JP2016508026A5/ja
Pending legal-status Critical Current

Links

JP2015542310A 2012-11-20 2013-11-20 前立腺癌を有する個体の予後診断方法 Pending JP2016508026A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE1251310 2012-11-20
SE1251310-7 2012-11-20
SE1350602-7 2013-05-16
SE1350602 2013-05-16
PCT/EP2013/074270 WO2014079874A1 (en) 2012-11-20 2013-11-20 Prognostic method for individuals with prostate cancer

Publications (2)

Publication Number Publication Date
JP2016508026A JP2016508026A (ja) 2016-03-17
JP2016508026A5 true JP2016508026A5 (enExample) 2017-01-05

Family

ID=49713059

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015542310A Pending JP2016508026A (ja) 2012-11-20 2013-11-20 前立腺癌を有する個体の予後診断方法

Country Status (8)

Country Link
US (2) US10428385B2 (enExample)
EP (1) EP2922970B1 (enExample)
JP (1) JP2016508026A (enExample)
AU (1) AU2013349721B2 (enExample)
CA (1) CA2891394C (enExample)
ES (1) ES2694409T3 (enExample)
RU (1) RU2669809C2 (enExample)
WO (1) WO2014079874A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108108590A (zh) 2012-03-05 2018-06-01 阿克蒂克合伙公司 分析系统和方法
DK2922967T3 (en) 2012-11-20 2018-04-16 Phadia Ab PROCEDURE FOR VIEWING A PRESENCE OR NON-PRESENCE OF AGGRESSIVE PROSTATANCES
AU2015230017B2 (en) * 2014-03-11 2021-06-17 A3P Biomedical Ab Method for detecting a solid tumor cancer
MX392384B (es) 2014-03-28 2025-03-24 Opko Diagnostics Llc Composiciones y metodos relacionados con el diagnostico de cancer de prostata.
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
EP3253800B1 (en) 2015-03-27 2021-03-03 Opko Diagnostics, LLC Prostate antigen standards and uses thereof
HK1247824A1 (zh) * 2015-04-29 2018-10-05 欧普科诊断有限责任公司 用於主动监控前列腺癌的组合物和方法
JP6570929B2 (ja) * 2015-09-08 2019-09-04 国立研究開発法人農業・食品産業技術総合研究機構 特性推定モデル生成装置および方法、解析対象の特性推定装置および方法
US20190345565A1 (en) * 2017-02-01 2019-11-14 Phadia Ab Method for indicating a presence or non-presence of prostate cancer in individuals with particular characteristics
WO2019144112A1 (en) * 2018-01-22 2019-07-25 Phadia Ab Method for the harmonization of assay results

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
BRPI0807236A2 (pt) 2007-02-07 2019-09-24 Decode Genetics Ehf métodos para determinar uma suscetibilidade para câncer de próstata em um indivíduo humano, para identificar um marcador para uso em avaliação de suscetibilidade para câncer de próstata e para genotipificar uma amostra de ácido nucleico obtida de um indivíduo humano sob risco de, ou diagnosticado com, câncer de prostáta, para avaliar um indivíduo humano para probabiliade da resposta a um agente terapêutico para prevenir e/ou melhorar sintomas associados com câncer de próstata, para predizer prognóstico de um indivíduo diagnosticado com câncer e para monitorar progresso de um tratamento de um indivíduo sofrendo tratamento para câncer de próstata, kit para avaliar suscetibilidade para câncer de próstata em um indivíduo humano, uso de uma sonda de oligonucleotídeo, meio legível por computador, e , aparelho para determinar um indicador genético para câncer de próstata em um indivíduo humano.
US9732389B2 (en) 2010-09-03 2017-08-15 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk
US20120202888A1 (en) 2010-10-08 2012-08-09 The Brigham And Women's Hospital, Inc. Biomarkers of prostate cancer and predicting mortality
US20120150032A1 (en) * 2010-12-13 2012-06-14 Julius Gudmundsson Sequence Variants Associated with Prostate Specific Antigen Levels
CA2871877A1 (en) 2012-05-16 2013-11-21 Phadia Ab Method for indicating the presence or non-presence of prostate cancer
DK2922967T3 (en) 2012-11-20 2018-04-16 Phadia Ab PROCEDURE FOR VIEWING A PRESENCE OR NON-PRESENCE OF AGGRESSIVE PROSTATANCES

Similar Documents

Publication Publication Date Title
JP2016503301A5 (enExample)
AU2021232712B2 (en) Method for detecting a solid tumor cancer
Takeuchi et al. The prognostic impact of the platelet distribution width-to-platelet count ratio in patients with breast cancer
Okamura et al. Preoperative neutrophil to lymphocyte ratio and prognostic nutritional index predict overall survival after hepatectomy for hepatocellular carcinoma
Aly et al. Polygenic risk score improves prostate cancer risk prediction: results from the Stockholm-1 cohort study
Prensner et al. RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1
Bonne et al. Salivary biomarker development using genomic, proteomic and metabolomic approaches
JP2019049559A (ja) 侵攻性前立腺癌の存在または不存在を判定する方法
Martuszewski et al. Donor-derived cell-free DNA in kidney transplantation as a potential rejection biomarker: a systematic literature review
Wang et al. Identification of serum monocyte chemoattractant protein-1 and prolactin as potential tumor markers in hepatocellular carcinoma
JP2017508970A5 (enExample)
JP2015524052A (ja) 前立腺癌の存在または不存在の提示方法
ES2694409T3 (es) Método de pronóstico para individuos con cáncer de próstata
Irvine et al. Multiplex serum protein analysis identifies novel biomarkers of advanced fibrosis in patients with chronic liver disease with the potential to improve diagnostic accuracy of established biomarkers
Zhou et al. Prognostic value of interleukin 2 and interleukin 15 in peritumoral hepatic tissues for patients with hepatitis B-related hepatocellular carcinoma after curative resection
CN107657149B (zh) 用于预测肝癌患者预后的系统
JP2016526167A5 (enExample)
Wu et al. The prediction of epidermal growth factor receptor mutation and prognosis of EGFR tyrosine kinase inhibitor by serum ferritin in advanced NSCLC
Yasuda et al. Preoperative predictors of very early recurrence in patients with hepatocellular carcinoma beyond the Milan criteria
Liang et al. Prospective evaluation of operating characteristics of prostate cancer detection biomarkers
FI3577237T3 (fi) Menetelmä eturauhassyövän läsnäolon tai puuttumisen osoittamiseksi henkilöillä, joilla on tiettyjä ominaisuuksia
Yang et al. Gustative Roussy Immune Score is a Predictor for Major Pathological Response in Rectal Cancer: A Result from the Preoperative Intraarterial Chemoembolization Combined with Radiotherapy (PCAR) Study
US20250210192A1 (en) Methods for disease detection
Hu et al. Development of a redox-related prognostic signature for predicting biochemical-recurrence-free survival of prostate cancer
Marconi et al. Post partial nephrectomy surveillance imaging: an evidence-based approach